Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest of Karyopharm Therapeutics Inc. from 31 Dec 2014 to 31 Dec 2025

Taxonomy & unit: us-gaap: USD
Description: Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary: Karyopharm Therapeutics Inc. quarterly and annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD history and change rate from 31 Dec 2014 to 31 Dec 2025.
Karyopharm Therapeutics Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending 31 Dec 2025 was $102,265,000, a 231% decline year-over-year.
Karyopharm Therapeutics Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending 31 Dec 2025 was $195,996,000, a 157% decline year-over-year.
Karyopharm Therapeutics Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2025 was $195,996,000, a 157% decline from 2024.
Karyopharm Therapeutics Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was $76,365,000, a 47% increase from 2023.
Karyopharm Therapeutics Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was $142,776,000, a 13% increase from 2022.
Source SEC data: View on sec.gov

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Change (%)

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Change (%)

Karyopharm Therapeutics Inc. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q4 2025	$195,996,000	$102,265,000	-$71,376,000	-231%	01 Oct 2025	31 Dec 2025	10-K	13 Feb 2026	2025	FY
Q3 2025	$124,620,000	$33,093,000	-$1,049,000	-3.3%	01 Jul 2025	30 Sep 2025	10-Q	03 Nov 2025	2025	Q3
Q2 2025	$123,571,000	$37,212,000	-$61,071,000	-256%	01 Apr 2025	30 Jun 2025	10-Q	11 Aug 2025	2025	Q2
Q1 2025	$62,500,000	$23,426,000	+$13,865,000	+37%	01 Jan 2025	31 Mar 2025	10-Q	12 May 2025	2025	Q1
Q4 2024	$76,365,000	$30,889,000	+$10,818,000	+26%	01 Oct 2024	31 Dec 2024	10-K	13 Feb 2026	2025	FY
Q3 2024	$87,183,000	$32,044,000	+$2,450,000	+7.1%	01 Jul 2024	30 Sep 2024	10-Q	03 Nov 2025	2025	Q3
Q2 2024	$89,633,000	$23,859,000	+$56,362,000		01 Apr 2024	30 Jun 2024	10-Q	11 Aug 2025	2025	Q2
Q1 2024	$145,995,000	$37,291,000	-$3,219,000	-9.4%	01 Jan 2024	31 Mar 2024	10-Q	12 May 2025	2025	Q1
Q4 2023	$142,776,000	$41,707,000	-$3,274,000	-8.5%	01 Oct 2023	31 Dec 2023	10-K	13 Feb 2026	2025	FY
Q3 2023	$139,502,000	$34,494,000	+$1,785,000	+4.9%	01 Jul 2023	30 Sep 2023	10-Q	05 Nov 2024	2024	Q3
Q2 2023	$141,287,000	$32,503,000	+$16,438,000	+34%	01 Apr 2023	30 Jun 2023	10-Q	06 Aug 2024	2024	Q2
Q1 2023	$157,725,000	$34,072,000	+$7,197,000	+17%	01 Jan 2023	31 Mar 2023	10-Q	08 May 2024	2024	Q1
Q4 2022	$164,922,000	$38,433,000	-$77,032,000	-200%	01 Oct 2022	31 Dec 2022	10-K	19 Feb 2025	2024	FY
Q3 2022	$87,890,000	$36,279,000	+$15,427,000	+30%	01 Jul 2022	30 Sep 2022	10-Q	02 Nov 2023	2023	Q3
Q2 2022	$103,317,000	$48,941,000	+$4,507,000	+8.4%	01 Apr 2022	30 Jun 2022	10-Q	02 Aug 2023	2023	Q2
Q1 2022	$107,824,000	$41,269,000	+$15,996,000	+28%	01 Jan 2022	31 Mar 2022	10-Q	04 May 2023	2023	Q1
Q4 2021	$123,820,000	$38,599,000	+$81,958,000		01 Oct 2021	31 Dec 2021	10-K	29 Feb 2024	2023	FY
Q3 2021	$205,778,000	$51,706,000	+$1,745,000	+3.3%	01 Jul 2021	30 Sep 2021	10-Q	03 Nov 2022	2022	Q3
Q2 2021	$207,523,000	$53,448,000	-$7,159,000	-15%	01 Apr 2021	30 Jun 2021	10-Q	04 Aug 2022	2022	Q2
Q1 2021	$200,364,000	$57,265,000	-$4,400,000	-8.3%	01 Jan 2021	31 Mar 2021	10-Q	05 May 2022	2022	Q1
Q4 2020	$195,964,000	$43,359,000	+$5,286,000	+11%	01 Oct 2020	31 Dec 2020	10-K	17 Feb 2023	2022	FY
Q3 2020	$201,250,000	$53,451,000	-$12,104,000	-29%	01 Jul 2020	30 Sep 2020	10-Q	03 Nov 2021	2021	Q3
Q2 2020	$189,146,000	$46,289,000	-$2,882,000	-6.6%	01 Apr 2020	30 Jun 2020	10-Q	05 Aug 2021	2021	Q2
Q1 2020	$186,264,000	$52,865,000	+$13,286,000	+20%	01 Jan 2020	31 Mar 2020	10-Q	04 May 2021	2021	Q1
Q4 2019	$199,550,000	$48,645,000	+$9,548,000	+16%	01 Oct 2019	31 Dec 2019	10-K	01 Mar 2022	2021	FY
Q3 2019	$209,098,000	$41,347,000	+$6,722,000	+14%	01 Jul 2019	30 Sep 2019	10-Q	02 Nov 2020	2020	Q3
Q2 2019	$215,820,000	$43,407,000	-$9,735,000	-29%	01 Apr 2019	30 Jun 2019	10-Q	04 Aug 2020	2020	Q2
Q1 2019	$206,085,000	$66,151,000	-$27,704,000	-72%	01 Jan 2019	31 Mar 2019	10-Q	05 May 2020	2020	Q1
Q4 2018	$178,381,000	$58,193,000	-$19,162,000	-49%	01 Oct 2018	31 Dec 2018	10-K	24 Feb 2021	2020	FY
Q3 2018	$159,219,000	$48,069,000	-$17,442,000	-57%	01 Jul 2018	30 Sep 2018	10-Q	04 Nov 2019	2019	Q3
Q2 2018	$141,777,000	$33,672,000	-$4,303,000	-15%	01 Apr 2018	30 Jun 2018	10-Q	07 Aug 2019	2019	Q2
Q1 2018	$137,474,000	$38,447,000	-$8,553,000	-29%	01 Jan 2018	31 Mar 2018	10-Q	09 May 2019	2019	Q1
Q4 2017	$128,921,000	$39,031,000	-$12,235,000	-46%	01 Oct 2017	31 Dec 2017	10-K	26 Feb 2020	2019	FY
Q3 2017	$116,686,000	$30,627,000	-$5,202,000	-20%	01 Jul 2017	30 Sep 2017	10-Q	08 Nov 2018	2018	Q3
Q2 2017	$111,484,000	$29,369,000	+$789,000	+2.6%	01 Apr 2017	30 Jun 2017	10-Q	07 Aug 2018	2018	Q2
Q1 2017	$112,273,000	$29,894,000	-$2,835,000	-10%	01 Jan 2017	31 Mar 2017	10-Q	10 May 2018	2018	Q1
Q4 2016	$109,438,000	$26,796,000			01 Oct 2016	31 Dec 2016	10-K	28 Feb 2019	2018	FY
Q3 2016		$25,425,000			01 Jul 2016	30 Sep 2016	10-Q	02 Nov 2017	2017	Q3
Q2 2016		$30,158,000			01 Apr 2016	30 Jun 2016	10-Q	08 Aug 2017	2017	Q2
Q1 2016		$27,059,000			01 Jan 2016	31 Mar 2016	10-Q	04 May 2017	2017	Q1

Karyopharm Therapeutics Inc. Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
2025	$195,996,000	-$119,631,000	-157%	01 Jan 2025	31 Dec 2025	10-K	13 Feb 2026	2025	FY
2024	$76,365,000	+$66,411,000	+47%	01 Jan 2024	31 Dec 2024	10-K	13 Feb 2026	2025	FY
2023	$142,776,000	+$22,146,000	+13%	01 Jan 2023	31 Dec 2023	10-K	13 Feb 2026	2025	FY
2022	$164,922,000	-$41,102,000	-33%	01 Jan 2022	31 Dec 2022	10-K	19 Feb 2025	2024	FY
2021	$123,820,000	+$72,144,000	+37%	01 Jan 2021	31 Dec 2021	10-K	29 Feb 2024	2023	FY
2020	$195,964,000	+$3,586,000	+1.8%	01 Jan 2020	31 Dec 2020	10-K	17 Feb 2023	2022	FY
2019	$199,550,000	-$21,169,000	-12%	01 Jan 2019	31 Dec 2019	10-K	01 Mar 2022	2021	FY
2018	$178,381,000	-$49,460,000	-38%	01 Jan 2018	31 Dec 2018	10-K	24 Feb 2021	2020	FY
2017	$128,921,000	-$19,483,000	-18%	01 Jan 2017	31 Dec 2017	10-K	26 Feb 2020	2019	FY
2016	$109,438,000	+$8,743,000	+7.4%	01 Jan 2016	31 Dec 2016	10-K	28 Feb 2019	2018	FY
2015	$118,181,000	-$42,404,000	-56%	01 Jan 2015	31 Dec 2015	10-K	15 Mar 2018	2017	FY
2014	$75,777,000			01 Jan 2014	31 Dec 2014	10-K	16 Mar 2017	2016	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.